"Sharing data is crucial to further research in Hematological Malignancies because many of these cancers are heterogeneous in terms of their genetic profile. Many genetic profiles are rare; many account for <10% cases. To ascertain the prognostic or predictive value of genetic biomarkers, researchers need to study large cohorts of patients. This is only achievable by sharing data."Anthony Moorman, Newcastle University, HARMONY Key Opinion Leaders for Childhood Leukemia
"HARMONY is a Network of Excellence in Hematology that goes beyond scientific collaboration to integrate the efforts of all Healthcare System Stakeholders. Ultimately, HARMONY aims to facilitate the access to the right treatment for the right patient at the right time."Jesús María Hernández Rivas, HARMONY Coordinator, Research group in Molecular Cytogenetics, IBSAL
"HARMONY Alliance is the largest European public-private partnership initiative aiming to improve the outcomes of patients with hematological malignancies through the use of big data sharing among all relevant stakeholders involved."Guillermo Sanz, HARMONY Co-Chair, Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana.
"HARMONY will to allow us to understand the outcomes that matter to patients and through the big data platform, identify targets, risk factors or treatments which will accelerate access of treatments to patients. The collaborative nature of HARMONY, with clinicians, cooperative groups, patients, regulatory authorities, HTA bodies and the pharmaceutical industry, an important way forward to ensure we can jointly achieve these challenging objectives and ensure faster access to innovation for patients with significant unmet needs in hematology."Pam Bacon, HARMONY Co-Lead, Celgene
“HARMONY is boldly addressing the collective action problem related to the use of health data for research and care provision - in one single go. Public and private partners have really come together to share, integrate and analyse clinical, genomic and real-world data to improve the health outcomes of cancer patients and address the challenges that cancer care faces.”Frederico Calado, HARMONY Lead, Novartis